Clinical
Follow pivotal data releases and trial developments that create new strategic pressure for biotech and pharma operators.
50 signals
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.
CLINICAL
A Phase 1 trial for tomivosertib in relapsed or refractory acute myeloid leukemia is set to begin, utilizing Bayesian optimal interval dose finding design.
CLINICAL
A Phase I/II study is underway to evaluate TROP2 CAR/IL-15 engineered NK cells combined with belzutifan in pancreatic cancer.
CLINICAL
This trial is investigating the safety and efficacy of olaparib in combination with radium-223 for patients with metastatic castration-resistant prostate cancer.
CLINICAL
A phase I trial is evaluating the safety and efficacy of triapine combined with radiation therapy for recurrent glioblastoma or astrocytoma.
CLINICAL
A pilot phase I trial is evaluating the combination of atezolizumab with rituximab, gemcitabine, and oxaliplatin in patients with relapsed/refractory transformed diffuse large B-cell lymphoma.
CLINICAL
A phase I/II trial is evaluating the safety and efficacy of atezolizumab combined with cabozantinib in patients with recurrent glioblastoma.
CLINICAL
The trial evaluates the safety and efficacy of iadademstat combined with atezolizumab or durvalumab in extensive stage small cell lung cancer.
CLINICAL
A phase I/II trial is evaluating the safety and efficacy of selinexor combined with radiation therapy in children with DIPG and HGG.
CLINICAL
A phase I trial is investigating the safety and dosing of EGFR/IL13Rα2 pool-CAR T cells administered locoregionally for recurrent or progressive high-grade gliomas.
CLINICAL
The trial evaluates side effects of proton therapy versus intensity modulated radiation therapy in post-surgical patients.
CLINICAL
A phase I clinical trial is underway to assess the safety and tolerability of THE-0504 in patients with solid tumors.
COMPETITIVE
A Phase 1/2 study is underway to evaluate investigational agents with or without pembrolizumab in patients with advanced esophageal squamous cell carcinoma.
CLINICAL
A Phase 1 single ascending dose study is underway to evaluate the safety and pharmacokinetics of LAI MMV055 alone and in combination with MMV371 in healthy participants.
CLINICAL
Genrix has initiated Phase I clinical trial for GR2301 injection to assess its safety and pharmacokinetics in healthy adults.
CLINICAL
A phase I trial is underway to evaluate the safety and tolerability of olaparib combined with durvalumab and radiation therapy in patients with locally advanced unresectable pancreatic cancer.
CLINICAL
A phase I clinical trial indicates that N-acetylcysteine may slow cone degeneration in patients with retinitis pigmentosa.
COMPETITIVE
A Phase I/II study is underway to evaluate the safety and efficacy of autologous T cells engineered to express CD20-specific CAR in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
CLINICAL
Novartis is conducting Phase I/II trial to evaluate the safety and tolerability of ERW316 alone and in combination with endocrine therapies in HR+/HER2- breast cancer.
CLINICAL
A phase I trial is investigating the combination of rituximab, lenalidomide, and ibrutinib in patients with untreated stage II-IV follicular lymphoma.
CLINICAL
A Phase 1 first-in-human trial is underway to evaluate M3T01, a monoclonal antibody targeting FasL, in patients with metastatic or unresectable solid tumors.
CLINICAL
A Phase 1/2 open-label study is underway to evaluate TSHA-105 for SLC13A5 Citrate Transporter Disorder.
CLINICAL
A phase I/II trial is evaluating the efficacy and safety of inotuzumab ozogamicin combined with chemotherapy in patients with acute lymphoblastic leukemia.
CLINICAL
A phase I trial is underway to evaluate the safety and efficacy of lenalidomide combined with nivolumab in treating primary CNS lymphoma.
CLINICAL
A Phase I open-label trial is underway to evaluate the safety of pembrolizumab in patients with neurological symptoms following COVID-19.
CLINICAL
Genentech is conducting a first-in-human Phase I/II study of GDC-7035 targeting KRAS G12D mutations in advanced solid tumors.
Showing 1–25 of 50 records